|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.
|
23720052 |
2013 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
[Expression of early placenta insulin-like growth factor (EPIL) in breast cancer cells provides an autocrine loop with enhancement of predominantly HER-2-related invasivity].
|
18035692 |
2005 |
|
Mammary Neoplasms
|
0.500 |
Therapeutic
|
group |
CTD_human |
[Efficacy and toxicity of trastuzumab combined vinorelbine in 21 patients with HER2 overexpressing metastatic breast cancer].
|
18819904 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
[Efficacy and toxicity of trastuzumab combined vinorelbine in 21 patients with HER2 overexpressing metastatic breast cancer].
|
18819904 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Women with HER2-positive breast tumors measuring ≥2 cm (median=5 cm) were randomized in a 1:2 ratio to 12 vs. 24 weeks of lapatinib and trastuzumab.
|
31662331 |
2020 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
With this in mind, we examined breast tumor cells for their sensitivity to the ErbB2 and FGFR inhibitors, PKI166 and PD173074, respectively.
|
15377668 |
2004 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
|
26334217 |
2015 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
While HER2 amplifications appear to be prevalent in select non-breast tumors, lapatinib monotherapy is associated with modest activity.
|
20857170 |
2012 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
When targeted by anti-HER2 immunoliposomes encapsulating quenched nitroxides, Hc7 cells, which are novel HER2-overexpressing cells derived from the MCF7 breast tumor cell line, endocytose the liposomes copiously, in contrast to the parent MCF7 cells or control CV1 cells, which do not express HER2.
|
20066490 |
2010 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We used this high throughput sequencing technology to analyze ERBB2 mutational status in five ERBB2 amplified cell lines (four breast, one ovarian) and two breast tumors.
|
18418848 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
We used this high throughput sequencing technology to analyze ERBB2 mutational status in five ERBB2 amplified cell lines (four breast, one ovarian) and two breast tumors.
|
18418848 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2.
|
12527905 |
2003 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2.
|
12527905 |
2003 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We used fluorescence in situ hybridization to study copy number aberrations of both topoIIalpha and ErbB-2 in nine breast cancer cell lines and in 97 clinical breast tumors, which were selected for the study according to their ErbB-2 status by Southern blotting.
|
10702400 |
2000 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We used CD151 gene-deleted mice expressing the MMTV-ErbB2 transgene to show that CD151 strongly supports ErbB2+ mammary tumor initiation and metastasis.
|
22952421 |
2012 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We used a label-free liquid chromatography-mass spectrometry (LC-MS) proteomic approach to compare plasma samples from patients with HER2-positive breast tumors and patients with HER2-negative tumors.
|
25434795 |
2015 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We tested 100 excised lymph node-negative breast tumors, using fluorescence in situ hybridization (FISH) with a biotinylated HER-2/neu DNA probe and immunohistochemical assays (IHC) with 2 different antibodies.
|
11371225 |
2001 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug.
|
7912163 |
1994 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We studied the feasibility of using real-time quantitative PCR to determine HER-2 DNA amplification and mRNA expression in microdissected formalin-fixed, paraffin-embedded breast tumors and compared this with standard immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) methods.
|
14736826 |
2004 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We studied the expression of AP-1 members at the mRNA level in 72 primary breast tumors and 37 adjacent non-tumor tissues and evaluated its correlation with clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status.
|
24073962 |
2013 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We studied the correlation of findings made by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) staining and the possibility of combining IHC and other clinicopathologic characteristics of breast tumors to predict FISH-determined HER-2/neu status.
|
16297088 |
2005 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We studied the concordance of Her-2/neu and topoisomerase IIalpha amplification in primary breast tumors and their metastases by immunostaining and DNA in situ hybridization.
|
11454672 |
2001 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We studied effects on differentiation and cell death of erbB-2/neu during mammary-gland development in transgenic mice expressing an activated, oncogenic rat erbB-2/neu gene controlled by the mammary-gland-specific promoter from mouse-mammary-tumor virus (MMTV-LTR).
|
10699933 |
2000 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We studied HER2 status using both IHC and fluorescence in situ hybridization (FISH) in 150 consecutive breast tumors submitted to our laboratory after a negative IHC result in local testing centers.
|
24045554 |
2013 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We speculate that, in addition to the oncogenic potential of erbB-2 overexpression, the unbalanced action of MLN64 contributes to the poor clinical outcome of breast tumors bearing this amplified region.
|
12802284 |
2003 |